| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology and medicine. What is described is an active immunostimulating vaccine containing at least one RNA, preferentially iRNA coding at least two antigens evoking the immune response in a mammal and used for treating lung cancer, first non-small cells lung cancer (NSCLC), preferentially specified among three primary subtypes, squamous cell carcinoma, adenocarcinoma and large-cell lung carcinoma, or NSCLS-related disorders.EFFECT: there are produced kits, first containing the active immunostimulating vaccine.21 cl, 34 dwg, 1 tbl, 8 ex |
